CoChat

Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs: A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia

Darkow, Theodore, Henk, Henry J, Thomas, Simu K, Feng, Weiwei, Baladi, Jean-Francois, Goldberg, George A, Hatfield, Alan, Cortes, Jorge · 2007 · PharmacoEconomics

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Objectives Identify treatment interruptions and non-adherence with imatinib; examine the clinical and patient characteristics related to treatment interruptions and non-adherence; and estimate the association between treatment interruptions and non-adherence with imatinib and healthcare costs for US managed care patients with chronic myeloid leukaemia (CML). Methods This retrospective analysis utilised electronic healthcare claims data from a US managed care provider. Adult patients with CML (as determined by International Classification of Diseases, ninth revision, Clinical Modification [ICD-9-CM] diagnosis code) were identified who began treatment with imatinib from 1 June 2001 through 31 March 2004. Treatment interruptions (i.e. failure to refill imatinib within 30 days from the run-out date of the prior prescription) were identified during the 12-month follow-up period. Medication possession ratio (MPR), calculated as total days' supply of imatinib divided by 365, was also examined. Healthcare costs (i.e. paid amounts for all prescription medications and medical services received, including health plan and patient liability) were examined in three ways: (i) total healthcare costs; (ii) total healthcare costs exclusive of imatinib costs; and (iii) total medical costs. All costs were converted to US dollars (2004 values) using the medical component of the Consumer Price Index. MPR was modelled using ordinary least squares regression. Presence of treatment interruptions was…

Overview

Integrity signals

Registry

Crossref · 10.2165/00019053-200725060-00004

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Research works printed but not linked: 4

  1. Deininger, 2005, Hematology (Am Soc Hematol Educ Program), 174-, 82
  2. Merante, 2005, Haematologica, 90, 979
  3. Schultz, 2005, Am J Manag Care, 11, 306
  4. Shalansky, 2002, Ann Pharmacother, 36, 1532, 10.1345/aph.1C044 · doi:10.1345/aph.1c044 · Paper page

Cited by

See all 271

Metadata

Authors
Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J.
Affiliations
Novartis (United States) (US)
Corresponding author
Darkow, Theodore
Venue
PharmacoEconomics
Published
2007
Volume
25
Issue
6
Pages
481-496
ISSN
1170-7690 (ISSN-L)
OpenAlex
W1606656369
Cited by
271
References
50
Citations by year
2026: 1 · 2025: 5 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 13 · 2020: 16 · 2019: 17 · 2018: 15 · 2017: 18 · 2016: 11 · 2015: 26 · 2014: 23 · 2013: 30 · 2012: 27
FWCI
9.79
Type
journal article
Language
en
Open access
closed
Locations
  • PharmacoEconomics (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Novartis Pharmaceuticals Corporation
  • H2020 European Research Council
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
Keywords
imatinib, chronic myeloid leukemia, treatment interruption, medication non-adherence, medication possession ratio, health care costs, managed care, concomitant medications, sex differences, starting dose, prescription refills, patient characteristics, cost-effectiveness, quality of care, patient satisfaction, patient-provider communication, medication adherence interventions
MeSH terms
Imatinib Mesylate, Adolescent, Adult, Aged, Antineoplastic Agents, Benzamides, Female, Humans, Male, Managed Care Programs, Middle Aged, Piperazines, Drug Prescriptions, Pyrimidines, Retrospective Studies, United States, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Treatment Refusal, Drug Costs, Health Care Costs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs: A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia. https://app.cochat.ai/papers/10.2165/00019053-200725060-00004
The paper
Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007). Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs: A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia. PharmacoEconomics. https://doi.org/10.2165/00019053-200725060-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.